<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03149419</url>
  </required_header>
  <id_info>
    <org_study_id>CAAE 6717515.1.0000.5259</org_study_id>
    <nct_id>NCT03149419</nct_id>
  </id_info>
  <brief_title>Hot Flash as a Marker of Cardiovascular Risk in Recent Postmenopause: Effects of Non-hormonal Treatments</brief_title>
  <official_title>Endothelial, Autonomic and Pressure Effects of Paroxetine in Recent Postmenopause Women With Hot Flashes: a Randomized Placebo Controlled Clinical Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Rio de Janeiro State University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Rio de Janeiro State University</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      Hot flashes, vasomotor symptoms that affect many postmenopausal women, are associated with
      cardiovascular disease and endothelial dysfunction. Estrogen therapy, associated or not with
      progestogens, is the standard treatment for vasomotor symptoms and improves the endothelial
      function of postmenopausal women with hot flushes, even those with cardiovascular risk
      factors, such as hypertension. It is not known whether hot flushes are a cause for the
      development of endothelial dysfunction or are markers of this dysfunction, evidenced by
      estrogen deficiency, thus representing primitive target organ (vessel) lesion. Paroxetine was
      approved by the FDA as a non hormonal treatment for menopausal hot flashes. In this
      double-blind randomized clinical trial, the vascular effects of paroxetine at a dose of 7.5
      mg / day, compared to placebo, during 12 weeks are evaluated.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Paroxetine and placebo effects at baseline and after 12 weeks in endothelial, autonomic and
      pressure components of vascular function are evaluated.

      Non invasive venous occlusion plethysmography is used to study endothelial function;
      ambulatory blood pressure monitoring is used to study blood pressure variations during
      daytime and nocturnal descent; autonomic function is studied following sympathetic and
      parasympathetic parameters through heart rate variability.

      The effects of paroxetine and placebo are also evaluated on:

        -  daytime sleepiness (through Epworth Sleepiness Scale ),

        -  sleep quality (through Pittsburgh Sleep Quality Index),

        -  perceived stress (through Perceived Scale Stress).

      Biochemical and hormonal profiles including complete lipid profile, fasting glucose, insulin,
      estradiol, follicle stimulating hormone (FSH), luteinizing hormone (LH); inflammatory and
      oxidative stress markers are also studied.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">March 1, 2016</start_date>
  <completion_date type="Actual">March 30, 2018</completion_date>
  <primary_completion_date type="Actual">September 30, 2017</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Endothelial function in non invasive venous occlusion plethysmography</measure>
    <time_frame>12 weeks</time_frame>
    <description>Forearm blood flow (ml/min per 100 ml)</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">140</enrollment>
  <condition>Postmenopausal Flushing</condition>
  <condition>Cardiovascular Risk Factor</condition>
  <condition>Endothelial Dysfunction</condition>
  <arm_group>
    <arm_group_label>Paroxetine</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Paroxetine 7,5 mg - 1 pill/day for 12 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo oral capsule (corn starch) - 1 pill/day for 12 weeks</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Paroxetine</intervention_name>
    <arm_group_label>Paroxetine</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo oral capsule</intervention_name>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Postmenopause

          2. Present hot flushes (note ≥ 3 on a scale of 0 to 10)

        Exclusion Criteria:

          1. &gt; 10 years of hypoestrogenism

          2. Smoking

          3. Diabetes mellitus or altered fasting glycemia in use of oral hypoglycemic agents or
             insulin

          4. BMI ≥ 35 Kg / m2

          5. Uncontrolled hypertension - blood pressure (BP) ≥ 140/90 mmHg

          6. Users of glucocorticoids, phytoestrogens, β-blockers, selective serotonin reuptake
             inhibitors (SSRIs), selective noradrenaline reuptake inhibitors (SNRIs), clonidine,
             gabapentin, pregabalin, cinnarizine, alphamethyldopa or any drugs with effects on the
             central nervous system;

          7. Uncompensated hypo or hyperthyroidism;

          8. Previous cardiovascular event history.
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>45 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ciciliana MZ Rech</last_name>
    <role>Principal Investigator</role>
    <affiliation>Universidade do Estado do Rio de Janeiro- BioVasc laboratory</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Ruth Clapauch, PhD</last_name>
    <role>Study Chair</role>
    <affiliation>Rio de Janeiro State University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Universidade do Estado do Rio de Janeiro</name>
      <address>
        <city>Rio de Janeiro</city>
        <zip>20550-900</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Brazil</country>
  </location_countries>
  <reference>
    <citation>Taddei S, Virdis A, Ghiadoni L, Mattei P, Sudano I, Bernini G, Pinto S, Salvetti A. Menopause is associated with endothelial dysfunction in women. Hypertension. 1996 Oct;28(4):576-82.</citation>
    <PMID>8843881</PMID>
  </reference>
  <reference>
    <citation>Bechlioulis A, Kalantaridou SN, Naka KK, Chatzikyriakidou A, Calis KA, Makrigiannakis A, Papanikolaou O, Kaponis A, Katsouras C, Georgiou I, Chrousos GP, Michalis LK. Endothelial function, but not carotid intima-media thickness, is affected early in menopause and is associated with severity of hot flushes. J Clin Endocrinol Metab. 2010 Mar;95(3):1199-206. doi: 10.1210/jc.2009-2262. Epub 2010 Jan 15.</citation>
    <PMID>20080857</PMID>
  </reference>
  <reference>
    <citation>Lambrinoudaki I, Augoulea A, Armeni E, Rizos D, Alexandrou A, Creatsa M, Kazani M, Georgiopoulos G, Livada A, Exarchakou A, Stamatelopoulos K. Menopausal symptoms are associated with subclinical atherosclerosis in healthy recently postmenopausal women. Climacteric. 2012 Aug;15(4):350-7. doi: 10.3109/13697137.2011.618564. Epub 2011 Dec 1.</citation>
    <PMID>22132748</PMID>
  </reference>
  <reference>
    <citation>Silveira JS, Clapauch R, Souza Md, Bouskela E. Hot flashes: emerging cardiovascular risk factors in recent and late postmenopause and their association with higher blood pressure. Menopause. 2016 Aug;23(8):846-55. doi: 10.1097/GME.0000000000000641.</citation>
    <PMID>27219834</PMID>
  </reference>
  <reference>
    <citation>Orleans RJ, Li L, Kim MJ, Guo J, Sobhan M, Soule L, Joffe HV. FDA approval of paroxetine for menopausal hot flushes. N Engl J Med. 2014 May 8;370(19):1777-9. doi: 10.1056/NEJMp1402080.</citation>
    <PMID>24806158</PMID>
  </reference>
  <verification_date>April 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 18, 2017</study_first_submitted>
  <study_first_submitted_qc>May 9, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">May 11, 2017</study_first_posted>
  <last_update_submitted>April 10, 2018</last_update_submitted>
  <last_update_submitted_qc>April 10, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">April 12, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Rio de Janeiro State University</investigator_affiliation>
    <investigator_full_name>Ciciliana Maíla Zilio Rech</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <keyword>postmenopause</keyword>
  <keyword>paroxetine</keyword>
  <keyword>endothelial dysfunction</keyword>
  <keyword>blood pressure</keyword>
  <keyword>heart rate variability</keyword>
  <keyword>sleep quality</keyword>
  <keyword>perceived stress</keyword>
  <keyword>sleepiness</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hot Flashes</mesh_term>
    <mesh_term>Flushing</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Paroxetine</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

